We are live on ! Find out more
NKTR icon

Nektar Therapeutics
NKTR

214 hedge funds and large institutions have $376M invested in Nektar Therapeutics in 2022 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 68 increasing their positions, 73 reducing their positions, and 38 closing their positions.

New
Increased
Maintained
Reduced
Closed

45% more call options, than puts

Call options by funds: $48K | Put options by funds: $33K

0.25% less ownership

Funds ownership: 6.24% → 5.99% (-0.25%)

7% less repeat investments, than reductions

Existing positions increased: 68 | Existing positions reduced: 73

7% less funds holding

Funds holding: 230 → 214 (-16)

33% less capital invested

Capital invested by funds: $561M → $376M (-$185M)

34% less first-time investments, than exits

New positions opened: 25 | Existing positions closed: 38

Holders
214
Holders Change
-16
Holders Change %
-6.96%
% of All Funds
3.44%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
25
Increased
68
Reduced
73
Closed
38
Calls
$48K
Puts
$33K
Net Calls
+$15K
Net Calls Change
-$1.77M

Top Buyers

1
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$4.95M
2
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$4.19M
3
Federated Hermes
Federated Hermes
Pennsylvania
+$3.28M
4
ABG
Ally Bridge Group
New York
+$2.91M
5
BlackRock
BlackRock
New York
+$2.84M

Top Sellers

1
Wellington Management Group
Wellington Management Group
Massachusetts
-$36.4M
2
AllianceBernstein
AllianceBernstein
Tennessee
-$2.47M
3
Primecap Management
Primecap Management
California
-$2.46M
4
Morgan Stanley
Morgan Stanley
New York
-$2.13M
5
State Street
State Street
Massachusetts
-$1.68M
Name Holding Trade Value Shares
Change 		Change in
Stake
Invesco
1
Invesco
Georgia
$84.4M +$206K +4,255 +0.2%
BlackRock
2
BlackRock
New York
$81.2M +$2.84M +58,680 +3%
Vanguard Group
3
Vanguard Group
Pennsylvania
$52.1M -$320K -6,612 -0.4%
Primecap Management
4
Primecap Management
California
$35.4M -$2.46M -50,893 -5%
State Street
5
State Street
Massachusetts
$16.6M -$1.68M -34,754 -7%
Geode Capital Management
6
Geode Capital Management
Massachusetts
$7.78M +$380K +7,848 +4%
Jacobs Levy Equity Management
7
Jacobs Levy Equity Management
New Jersey
$5.81M +$4.95M +102,195 +148%
Citadel Advisors
8
Citadel Advisors
Florida
$4.25M +$2.19M +45,148 +56%
Northern Trust
9
Northern Trust
Illinois
$4.22M +$1.21K +25 +0%
Federated Hermes
10
Federated Hermes
Pennsylvania
$4.19M +$3.28M +67,723 +121%
Norges Bank
11
Norges Bank
Norway
$3.83M – – –
Morgan Stanley
12
Morgan Stanley
New York
$3.71M -$2.13M -43,975 -29%
Bank of New York Mellon
13
Bank of New York Mellon
New York
$3.69M -$284K -5,872 -5%
Charles Schwab
14
Charles Schwab
California
$3.11M +$54.5K +1,127 +1%
ABG
15
Ally Bridge Group
New York
$3.02M +$2.91M +60,114 +208%
Principal Financial Group
16
Principal Financial Group
Iowa
$2.66M +$10.4K +214 +0.3%
PAMS
17
Pictet Asset Management (Switzerland)
Switzerland
$2.61M +$954K +19,710 +34%
D.E. Shaw & Co
18
D.E. Shaw & Co
New York
$2.55M +$1.45M +29,933 +66%
Goldman Sachs
19
Goldman Sachs
New York
$2.45M -$60.1K -1,242 -2%
Ameriprise
20
Ameriprise
Minnesota
$2.02M +$319K +6,595 +12%
GCP
21
GSA Capital Partners
United Kingdom
$1.46M +$1.89M +39,050 +988%
B
22
Braidwell
Connecticut
$1.4M +$2M +41,352 New
Millennium Management
23
Millennium Management
New York
$1.39M +$1.47M +30,300 +287%
EP
24
Edgestream Partners
New Jersey
$1.38M -$1.42M -29,252 -42%
CS
25
Candriam SCA
Luxembourg
$1.35M -$290K -6,000 -13%
1
2 3 4 5

NKTR Hedge Fund Activity: Q4 2022 in Review

214 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Nektar Therapeutics (NKTR) for Q4 2022, worth a combined $376M — down 33% from $561M a quarter earlier.

Sellers outnumbered buyers: 38 funds closed out of NKTR and 25 opened new positions — a net loss of 13 holders — while 73 trimmed existing stakes and 68 added.

The largest buyer was Jacobs Levy Equity Management, adding an estimated $4.95M. The largest seller was Wellington Management Group, exiting entirely with an estimated $36.4M sold.

  • 214 institutional investors held Nektar Therapeutics (NKTR) as of Q4 2022, down from 230 in Q3 2022.
  • Funds reported $376M of Nektar Therapeutics stock for Q4 2022, down 33% quarter-over-quarter.
  • 25 funds opened new Nektar Therapeutics positions in Q4 2022 and 38 closed out, a net change of -13 holders.
  • The largest Nektar Therapeutics buyer in Q4 2022 was Jacobs Levy Equity Management, an estimated $4.95M added.
  • The largest Nektar Therapeutics seller in Q4 2022 was Wellington Management Group, an estimated $36.4M sold.

Based on aggregated 13F filings for Q4 2022.